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Introduction
Breast cancer (BC) is the most common cancer in women 
in Europe [1]. Despite surgery and adjuvant systemic 
therapy, many women with early BC still relapse and die 
of their disease. Minimal residual disease (MRD) after 
potentially curative surgery for BC is thought to contri-
bute to disease relapse and to be the target of adjuvant 
treatment. MRD is deﬁ   ned as micrometastatic cells 
undetectable by conventional imaging and laboratory 
tests. Surrogates of MRD are tumor cells detected in the 
bone marrow (disseminated tumor cells (DTCs)) and 
peripheral blood (circulating tumor cells (CTCs)) [2]. Th  e 
detection and characterization of DTCs/CTCs are 
expected to lead to personalized treatment strategies and 
accelerate the development of novel therapeutic agents 
for BC [2]. Furthermore, genotypic and phenotypic 
characterization of DTCs/CTCs at the single cell level 
may provide novel insights into the biology of tumor 
progression [3].
Detection methods
Th   e detection of DTCs/CTCs in BC is challenging since 
these cells are rare, occurring at a frequency of one tumor 
cell per 106 to 107 mononuclear cells. To isolate DTCs/
CTCs, enrichment techniques are therefore typically 
applied. Th   ese techniques are based either on the physical 
properties of the cells (for example, cell density by ﬁ  coll 
centrifugation or cell size by ﬁ   ltration) or on their 
immunological characteristics (for example, cell surface 
antigens of DTCs/CTCs by immuno  enrichment or 
markers of hematopoietic cells by immunodepletion). 
Ficoll centrifugation was widely used in the initial clinical 
studies of bone marrow DTCs [4]. Currently, however, 
enrichment techniques incorporating immunomagneti-
cally labeled monocolonal antibodies are more often used 
because they improve tumor cell recovery (recovery rates 
of >50% to 85%) [5,6] over ﬁ  coll enrichment (recovery 
rate of 40%) [7] in spiking experiments using cell lines. 
After the initial enrichment step, DTCs/CTCs have been 
detected using assays based on either antibodies 
(immuno cytochemistry,  immuno ﬂ  uorescence) or nucleic 
acids (mRNA transcripts by reverse transcription PCR 
(RT-PCR)). Table 1 summar  izes the main technologies 
for CTC detection in breast cancer.
Antibody-based assays
Since there are no universal tumor-speciﬁ  c  antigen/
genes, epithelial-speciﬁ  c antigens, including cytokeratins 
(CKs), epithelial cell adhesion molecule (EpCAM), and 
growth factor receptors (for example, human epidermal 
growth factor receptor (HER2)), have been used as 
markers of choice for the detection of DTCs/CTCs. In 
consensus meetings, the use of appropriate staining 
controls, directly labeled ﬂ   uorescent monoclonal anti-
bodies, identiﬁ   cation of DTCs/CTCs based on cyto-
morpho  logic criteria/phenotypic features, and validation 
by two independent observers have been suggested as 
measures to reduce false-positive results [8,9].
CellSearch® (Veridex, Warren, NJ, USA) is an auto-
mated enrichment and immunostaining system for CTC 
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an antibody against EpCAM to magnetically separate 
epithelial cells from whole blood [10]. Captured cells are 
stained with antibodies speciﬁ  c for cytokeratins 8, 18 and 
19 (pan-CK) and CD45 (speciﬁ   c for leucocytes) and 
stained with 4’6-diamidino-2-phenylindole-2 (DAPI; to 
conﬁ  rm the presence of a cell nucleus). A CTC is deﬁ  ned 
as a cell staining for pan-CK and DAPI, but not for CD45. 
Currently, CellSearch® is the only technology that has 
received US Food and Drug Administration (FDA) 
approval for CTC detection as an aid in monitoring 
patients with metastatic breast, colorectal and prostate 
cancer [10-12]. Th   e performance of CellSearch® for CTC 
detection in metastatic solid tumors has also been 
validated in ring studies [13,14].
Other technologies include the MagSweeper, which 
uses immunomagnetic separation and gently enriches 
target cells by 108-fold from blood, eliminating cells that 
are not bound to magnetic particles [6]. Th   is process has 
been shown to keep cell function intact and not to 
perturb rare cell gene expression [6]. CTCs have been 
also detected using multi-parameter ﬂ  ow cytometry, and 
their detection with this technology was associated with 
poor outcome in women with BC [15]. MAINTRAC®, 
another method, detects circulating epithelial tumor cells 
from whole unseparated blood, and uses a laser scanning 
cytometer after staining with anti-human epithelial and 
anti-CD45 ﬂ  uorescent antibodies [16]. Th  is technology 
results in CTC counts up to 105 per milliliter of blood in 
all women with early BC, consequently raising concerns 
about the speciﬁ  city of the method to detect tumor cells 
[16].
Advances in optical technologies have also improved 
DTC/CTC detection. Several slide-based automated 
microscopic scanning devices, such as the Ikoniscope® 
[17] and the Ariol® system [18,19], have been applied for 
standardized micrometastatic cell detection and charac-
teri  zation. Another approach has been developed that 
uses ﬁ   ber-optic array scanning technology (FAST) for 
rare cell detection [20]. It has been demonstrated that 
FAST cytometry is capable of a 500-fold increase in 
speed over automated digital microscopy, with com  para  ble 
sensitivity and superior speciﬁ  city [20]. Th  e  combination 
of FAST and automated digital microscopy has allowed 
investigators to detect rare epithelial cells from whole 
unseparated blood after immunoﬂ  uorescence  staining 
with a pan-CK antibody.
Nucleic acid-based assays
Nucleic acid-based assays have been initially hampered 
by false-positive results due to inability to assess tumor 
cell morphology, expression of target genes in normal 
cells, and the presence of pseudogenes (genes without 
protein-coding abilities) [21]. Newer quantitative assays 
have addressed some of these problems. To detect DTCs/
CTCs in breast cancer, nucleic acid-based assays, either 
as single genes or as part of multiplex assays [22-27], have 
mainly used CK19, mammaglobin-A (MGB1), HER2 and 
mucin 1 (MUC1) mRNA. Th   e AdnaTest® BreastCancerSelect 
(AdnaGen AG, Langenhagen, Germany) is a commer-
cially available molecular assay that utilizes immuno-
magnetic separation with antibodies against MUC1 and 
EpCAM followed by a multiplex RT-PCR for HER2, 
MUC1 and EpCAM [28].
Table 1. Technologies for circulating tumor cell detection in breast cancer
System Enrichment  Detection  FDA  approval  Reference
CellSearch®  EpCAM-coated ferrofl  uids  CK8, 18, 19+/DAPI+/CD45-  Yesa [10-12]
CTC-chip®  Microfl  uidics. EpCAM-coated microposts  CK+/CD45-/DAPI+  No  [29,34]
The CTChip®  Microfl  uidics. Enrichment based on   CK+  No  [31]
 physical  properties
Magsweeper®  EpCAM+ enrichment  Gene expression profi  ling  No  [6]
EPISPOT assay®  Depletion of CD45+ cells  CK19, MUC1  No  [35]
MAINTRAC® RBC  lysis EpCAM+/CD45-  No  [16]
Ariol®  RBC lysis, CK+, EpCAM+ enrichment  CK8, 18, 19+/DAPI+/CD45-  No  [19]
Fiber-optic array scanning technology (FAST)  No  CK+  No  [20]
Collagen adhesion matrix (CAM) assay  Invasion and digestion of cell adhesion  EpCAM+, panCK+/CD45-  No  [36]
AdnaTest®  MUC1+ and EpCAM+ enrichment  HER2, MUC1 and EpCAM  No  [28]
Single gene or multi-marker RT-PCR assays  Ficoll or EpCAM+ enrichment or   CK19, MGB1, HER2, MUC1 mRNA  No  [22-27]
  depletion of CD45+ cells
Multiparameter fl  ow cytometry  Ficoll enrichment  EpCAM+/CK8, 18, 19+/CD45-  No  [15]
CK, cytokeratin; EpCAM, epithelial cell adhesion molecule; FDA, Food and Drug Administration; HER, human epidermal growth factor receptor; MGB1, 
mammaglobin-A; MUC1, mucin 1; RBC, red blood cell. aApproval as an aid in monitoring patients with metastatic breast, colorectal and prostate cancer.
Ignatiadis and Reinholz Breast Cancer Research 2011, 13:222 
http://breast-cancer-research.com/content/13/5/222
Page 2 of 10Emerging detection technologies
Beyond immunomagnetic separators, microﬂ  uidic devices 
have been developed for rare cell tumor capture, and 
these involve non-electrokinetic methods, such as immo-
bili  zation via antibody [29] and size-based sorting [30,31], 
or electrokinetic methods (for example, dielectro  phor-
esis) [32]. An example of a microﬂ  uidic platform is the 
‘CTC-chip’, which is capable of eﬃ   cient  and  selective 
separation of viable CTCs from peripheral whole blood 
samples, mediated by the interaction of target CTCs with 
EpCAM-coated microposts under precisely controlled 
laminar ﬂ   ow conditions [29]. A direct comparison 
between CellSearch® and two commercially available 
CTC-chips showed that these platforms provided similar 
sensitivity and yield in patient samples [33]. Stott and 
colleagues [34] recently reported improved sensitivity of 
the CTC-chip for CTC detection in patients with 
localized prostate cancer.
Several other assays have also been developed. For 
example, a technique named EPISPOT (epithelial 
immuno  spot) allows detection of viable DTCs and CTCs 
owing to their ability to secrete individual proteins after 
48 hours of short-term culture [35]. A functional cell 
separation method called CAM, or the collagen adhesion 
matrix assay, was reported to detect CTCs with the 
invasive phenotype and to explore their molecular 
features [36]. Beyond these assays, new imaging proce-
dures have been developed for the in vivo detection of 
CTCs [37].
Several investigators have also evaluated the potential 
utility of circulating cell-free DNA, either as a surrogate 
to monitor MRD [38], or as a ‘liquid biopsy’ for real-time 
monitoring of tumor mutations in cancer patients [39]. 
Moreover, some investigators have been able to identify 
patient-speciﬁ   c genomic rearrangements in plasma-
circulating DNA as a way to monitor MRD [40]. Th  ey 
employed next-generation sequencing to rapidly identify 
patient-speciﬁ   c genomic rearrangements in primary 
tumors and showed that PCR assays could reliably detect 
these rearrangements in plasma [40]. A recent review has 
summarized advances in cell-free nucleic acids (DNA, 
mRNA, microRNA) as potential biomarkers in cancer [41].
Critical interpretation of detection technologies
Th  e  diﬀ  erent technologies use diﬀ  erent enrichment and 
detection steps and therefore do not always detect the 
same CTC population (Table 1). In a study comparing 
two commercially available assays (CellSearch® and 
AdnaTest®) in the same metastatic BC patient samples, 
the concordance between the two assays was 64% for 
CTC detection and 50% for HER2-positive CTC detec-
tion [42]. Th   erefore, it is important to study the clinical 
utility of the assay-dependent CTC detection and charac-
terization. Moreover, most enrichment methods used by 
the diﬀ  erent assays are biased because they result in loss 
of a fraction of CTCs due to tumor cell heterogeneity. As 
an example, some available technologies detect only 
EpCAM+ CTCs (Table 1). However, it has been shown 
that BC cell lines with low EpCAM expression and high 
expression of mesenchymal markers cannot be eﬃ   ciently 
captured using a purely EpCAM-based mechanism 
[33,43,44]. Some other technologies are using enrichment 
based on red blood cell lysis or leukocyte depletion 
(CD45-negative depletion) aiming at a less biased CTC 
enrichment (Table 1). Another critical issue with all cell 
detection technologies is that blood cannot be stored and 
must be processed soon after it has been drawn, within 
up to 72 hours [13] depending on the technology used. 
Th   ere  fore, the clinical validation of CTCs depends on the 
availability of detection technologies in diﬀ  erent  labs. 
Th   is is a major diﬀ  erence between CTCs and biomarkers 
from paraﬃ     n-embedded primary tumor blocks, for 
which real-time processing is not mandatory. Since all 
currently available platforms will continue to evolve 
rapidly, the challenge will be to prospectively evaluate the 
utility of each technology to address speciﬁ  c  clinical 
questions.
Clinical relevance of DTCs/CTCs
CTCs and DTCs were cited for the ﬁ  rst time in the 2007 
recommendations of the American Society of Clinical 
Oncology (ASCO) on tumor markers [45]. Recently, in 
the 7th edition of the American Joint Committee on 
Cancer Staging Manual (2010), a new M0(i+) category 
was proposed for TNM (tumor, node, metastasis) staging 
in BC [46]. Th   is new category is deﬁ  ned as no clinical or 
radiographic evidence of distant metastases, but deposits 
of molecularly or microscopically detected tumor cells 
(no larger than 0.2 mm) in blood, bone marrow, or other 
non-regional nodal tissue in a patient without symptoms 
or signs of metastases.
Clinical relevance of DTCs
Th   e inclusion of the M0(i+) category was driven at least 
in part by a pooled analysis of individual data from 
several studies, which showed that bone marrow CK-
positive DTCs were detected at the time of surgery in 
30.6% of 4,703 patients with invasive BC [4]. Bone 
marrow DTCs were signiﬁ  cantly more frequent in women 
with larger tumors, or tumors with higher histologic 
grade, hormone receptor negativity, and lymph node 
metastasis. In multivariate analysis, the presence of bone 
marrow DTCs predicted for signiﬁ  cantly higher risk of 
death from BC [4]. Recently, in the American College of 
Surgeons Oncology Group’s (ACOSOG) Z0010 multi-
center trial, bone marrow DTCs were identiﬁ  ed  at 
surgery by immunocytochemistry in only 105 of 3,491 
patients (3%) with clinical T1/T2 N0 M0 BC [47]. 
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marrow DTCs still signiﬁ  cantly predicted decreased overall 
survival [47]. A pooled analysis of individual patient data 
from 676 women with stage I-III BC from three studies 
showed that bone marrow DTCs were detected in 15.5% 
of patients at a median 37-month follow-up after 
diagnosis [48]. Th   e presence of DTCs was an independent 
indicator of poor prognosis and could be used to select 
patients for secondary adjuvant treatment strategies [48].
Clinical relevance of CTCs (CellSearch®)
Using CellSearch®, ≥5 CTCs/7.5 ml of blood were 
detected in 49% of 177 patients with measurable meta-
static BC before a new treatment was started [10]. CTC 
detection was an independent predictor of progression-
free survival and overall survival [10]. Th  is and other 
studies [49-52] have provided solid data about the 
adverse prognostic value when CTCs are detected by 
CellSearch® in metastatic BC.
Detecting CTCs in non-metastatic BC is more chal-
leng  ing because these cells occur at a very low frequency 
in this setting. Pierga and colleagues [53] found ≥1 
CTC/7.5 ml in 23% of 97 patients before administrating 
neoadjuvant chemotherapy (NAC) and in 17% of 86 
patients after NAC. Th  e detection of ≥1 CTC/7.5 ml 
before NAC, after NAC, or at both time points in the 
above study was associated with worse distant 
metastasis-free survival and overall survival at a median 
follow-up of 36 months [54]. In another study ≥1 
CTC/7.5 ml were detected in 21.6% of 213 patients before 
NAC and in 10.6% of 207 patients after NAC [55]. In both 
these studies, however, neither CTC detection before or 
after NAC, nor changes in CTC detection during treat-
ment, were predictive of pathological complete response 
[53,55]. Rack and colleagues [56] detected ≥1 CTC/22.5 
ml before the start of adjuvant treatment in 21.5% of 
2,026 patients with early BC [56]. In this study, pre-
treatment detection of CTCs was conﬁ   rmed as an 
indepen  dent predictor for both disease-free survival and 
overall survival [56]. Several other investigators have 
detected CTCs by CellSearch® in 9% to 38% of patients 
with early BC without reporting survival data [57-59].
Th  ese diﬀ  erences in CTC detection rate in early BC 
could be attributed to the Poisson distribution of rare 
events [60], to diﬀ  erences in patient populations, samp-
ling time points, blood volume analyzed, the use or not of 
ﬁ  coll enrichment before processing with CellSearch®, and 
diﬀ   erences in image interpretation between diﬀ  erent 
labs. Most women in this setting have only one detectable 
CTC/whole blood volume analyzed. Th  erefore, in order 
to prospectively test potential clinical applications of 
CTCs in non-metastatic BC, it is important to stan-
dardize image interpretation across labs by taking into 
account cytomorphologic criteria.
CTCs versus DTCs
Since blood is more easily obtained than bone marrow, 
an important question is whether peripheral blood CTCs 
can be used as surrogate markers for bone marrow DTCs. 
In one study, peripheral blood and bone marrow were 
collected from 341 patients at a median follow-up of 
40  months after initial surgery [61]. In this study, 8 
patients were CTC+/DTC+, 26 were CTC+/DTC-, and 
40 were CTC-/DTC+. Although both CTCs (10% of the 
patients) and DTCs (14% of the patients) were signiﬁ  -
cantly associated with worse clinical outcome, DTCs 
were more informative than CTCs [61]. Th  is and other 
studies [62] showed that there was no good correlation 
between CTC and DTC detection. However, it is not 
clear whether this is because CTCs and DTCs represent 
diﬀ  erent tumor cell populations or whether this is also 
related to limitations of the detection technologies used. 
At present there are no data to support that CTCs can 
replace DTCs.
Clinical relevance of nucleic acid-based assays
In early BC, initial single-center studies have reported 
that the detection of peripheral blood CK19 mRNA by 
RT-PCR after ﬁ  coll enrichment of mononuclear cells was 
an independent prognostic factor for reduced disease-
free survival and overall survival [63,64]. In another 
study, 13% of 431 early BC patients were CTC-positive 
according to the AdnaTest®; however, no correlation with 
clinical outcome was reported [65]. In metastatic BC, 
CTC detection by AdnaTest® was reported in 52% of 42 
women and predicted therapy response in 78% of cases 
[66]. Finally using immunomagnetic tumor cell enrich-
ment and a multi-marker quantitative PCR based assay, 
CTCs were detected in 7.9% of 733 stage I/II breast cancer 
patients with a median follow-up time of 7.6 years and 
their detection was an independent predictor of meta-
stasis-free survival and breast cancer speciﬁ  c survival [67]. 
However, despite these initial results, no nucleic acid-
based assay has received FDA approval nor has demon-
strated utility in treating patients with BC.
Clinical trials with DTCs/CTCs
Interestingly, CTC or DTC clearance after systemic treat-
ment has been used as an endpoint in BC clinical trials. 
In one single-center study, it was shown that a short 
course of trastuzumab (3 cycles every 3 weeks) eliminated 
chemotherapy-resistant  CK19 mRNA-positive cells in 
peripheral blood or bone marrow in 20 of 30 women with 
stage I-IV BC [68]. Another study randomized women 
with stage II and III BC to NAC with or without 
zolendronic acid [69]. Th   e primary endpoint of the trial 
was the number of patients with detectable DTCs at 
3  months’ post-treatment. At 3 months, DTCs were 
detected in 17 of 56 patients receiving zoledronic acid 
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women had detectable DTCs after NAC with concurrent 
zoledronic acid than with chemotherapy alone, this was 
not the case when only women who tested DTC-positive 
at baseline were analyzed. A critical question is if CTC 
clearance can be used as a ‘surrogate’ for survival for 
regulatory purposes. Such an eﬀ   ort is ongoing and 
investigators are studying CTC detection by CellSearch® 
before and after treatment in the phase 3 registration 
trials of abiraterone acetate in prostate cancer [70].
Although data on the adverse prognostic value of CTC 
d    etection by CellSearch® in metastatic BC are solid, 
evidence from prospective trials is needed that CTC 
detection can lead to changes in treatment decision and 
thus improve clinical outcome in metastatic BC. Such an 
eﬀ  ort is ongoing in a phase III trial run by the Southwest 
Oncology Group, which is testing the strategy of 
changing chemotherapy versus continuing the same 
chemotherapy for patients with metastatic BC who have 
elevated CTC levels at their ﬁ  rst follow-up assessment 
(ClinicalTrials.gov NCT00382018).
DTC/CTC characterization
Identifi  cation of therapeutic targets
Beyond enumeration, further characterization of DTCs 
and CTCs holds the promise to improve treatment 
outcome in women with BC. Because of the availability of 
anti-HER2 agents, HER2 expression was studied on 
DTCs [71-73] and CTCs [33,42,55,59,66,74-78] (Table 2) 
and was correlated with HER2 expression on the primary 
tumor. In most studies, HER2 expression on DTCs/CTCs 
is more prevalent in women with HER2-positive BC than 
in women with HER2-negative BC in both non-meta-
static and metastatic settings. Interestingly, among women 
with HER2-negative primary tumors deﬁ  ned by standard 
pathology and detectable CTCs, between 14% and 50% 
may have at least one HER2-positive CTC. However, it is 
not known whether the discordant cases can be attri  bu-
ted to technical causes or whether there is any underlying 
biological explanation. Clinical testing for HER2 in the 
primary tumor is known to result in false-negative and 
false-positive results [79]. Furthermore, in most cases 
diﬀ  erent technologies are used to evaluate HER2 in the 
primary tumor and the CTCs. Beyond technical issues, 
functional HER2 protein up-regulation on CTCs cannot 
be excluded, and the acquisition of HER2 ampliﬁ  cation 
during the course of the disease has been suggested [74]. 
It was shown that four out of nine patients with meta-
static BC whose primary tumors were HER2-negative 
and who had CTCs showing HER2 gene ampliﬁ  cation 
derived beneﬁ   t from trastuzumab-containing therapy 
[74].
Beyond HER2, several other markers have been studied 
on DTCs/CTCs. Markers related to angiogenesis, such as 
vascular endothelial growth factor (VEGF), VEGF2, and 
hypoxia inducible factor (HIF)-1α, were observed in 
CTC-positive samples from metastatic BC patients [80]. 
Using the CTC-chip technology to purify CTCs, epider-
mal growth factor receptor mutations conferring drug 
resistance were detected in CTCs from non-small-cell 
lung cancer patients who had received tyrosine kinase 
inhibitors [81]. Androgen receptor mutations were also 
identiﬁ   ed in CTC-enriched peripheral blood samples 
from castration-resistant prostate cancer patients [82]. In 
most of these studies, DTC/CTC characterization was 
performed in few patients in the metastatic setting, and 
therefore validation in independent larger patient series 
is required. Characterizing DTCs/CTCs in non-
metastatic tumors poses additional challenges since such 
cells are only rarely detected in this setting. Finally, 
clinical trials are needed to demonstrate that CTC 
characterization is important for patient management.
Identifi  cation of DTCs/CTCs with ‘tumor-initiating cell’ 
phenotype
Beyond the potential for improving patient outcome, the 
study of DTCs/CTCs aims to lead to a better under  stand-
ing of the metastatic process. Research has shown a 
signiﬁ  cant proportion of DTCs to be resistant to conven-
tional chemotherapy [48]. Furthermore, using Ki67 
immuno  staining, most micrometastatic cells have been 
found to be in a non-proliferative state [83]. Interestingly, 
the CD44+CD24-/low tumor-initiating cell phenotype [84] 
was observed in a signiﬁ  cant number of bone marrow 
DTCs using triple-staining by immunocytochemistry 
[85]. Moreover, the CK19+/MUC1 stem cell-like pheno-
type was demonstrated in a signiﬁ  cant number of DTCs 
in BC by the EPISPOT assay [35]. Epithelial mesencymal 
transition markers and aldehyde dehydrogenase 1 
(ALDH1) were also identiﬁ  ed in a major proportion of 
CTCs from patients with metastatic BC [86]. However, 
clinical studies are needed to associate the presence of 
CTCs/DTCs with tumor-initiating cell phenotype with 
clinical outcome in women with BC.
Tumor dormancy
An issue related to the role of DTCs in the metastatic 
process is determining which of them will grow into 
overt metastases and which will not. According to clinical 
studies on bone marrow DTCs, 50% to 70% of patients 
with detectable DTCs will not develop metastases, 
although even patients without DTCs may relapse and 
die of BC [4]. For patients who relapse without such cells 
detectable in their bone marrow, it is possible that the 
DTCs have actually settled into other organs; alterna-
tively, lack of DTCs could be the result of sampling error 
or reﬂ  ect the suboptimal sensitivity of CKs as a marker 
for DTC detection. Indeed, tumor cell dissemination has 
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down-regulation of epithelial cell markers [87]. Conver-
sely, it is possible that non-relapse in the case of patients 
with DTCs/CTCs can be attributed to the detection of 
apoptotic cells or to tumor dormancy. Interestingly, 
CTCs have been detected in one-third of women without 
clinical evidence of disease up to 22 years after mastec-
tomy for BC [88].
Th   ere is evidence that several mechanisms of dormancy 
exist, including cellular dormancy, in which DTCs enter a 
state of quiescence (G0-G1 arrest), and tumor mass 
dormancy, in which DTCs divide but the lesion does not 
grow beyond a certain size [89]. Th  ere is also evidence 
that mechanisms regulating the switch between cellular 
dormancy and escape from it are related to the cross-talk 
between DTCs and the microenvironment [89,90]. For 
example, loss or absence of a surface receptor like HER2, 
urokinase-type plasminogen activator receptor (uPAR) 
or integrins that transduce growth signals from the 
microenvironment may result in a dormant DTC, 
whereas the presence of such a receptor and a permissive 
microenvironment may result in a proliferating DTC. 
Interestingly, the overexpression of HER2 [71] or uPAR 
[91] on DTCs was associated with poor prognosis in 
patients with breast and gastric cancer, respectively.
Th  e mechanisms that regulate the switch between 
tumor mass dormancy and expansion have been suggest-
ed to be related to angiogenesis [92] and the immune 
Table 2. HER2 expression on circulating tumor cells and primary breast cancer
                                          HER2+ CTCs/total CTCs (%)
    Enrichment/detection; CTC positive; 
Stage  HER2 PT  CTC HER2 positive  CTC detection rate  HER2- PT  HER2+ PT  Reference
M0 and M1  FISH  EpCAM+ enrichment, C11, anti-CD45 (Her 81)  NA  9/24 (37%)  11 of 15 (73%)  [74]
    HER2 CTC: IF, 0, 1+, 2+, 3+, FISH       
    HER2+ CTCs: IF (3+), FISH HER2/CEP17 ≥2.0       
M0  IHC, FISH  Ficoll, immunomagnetic separation  17/35 (49%)  12/24 (50%)  2/3 (67%)  [75]
    ICC CK, HER2 (21N clone)       
    ≥1 HER2+ CTC/50 ml       
M0  IHC, FISH  CellSearch®  Before NAC: 46/213 (22%)  8/37 (21%)  6/21 (28%)  [55]
    ≥1 CTC/7.5 ml  After NAC: 22/107 (11%)     
    ≥1 HER2 (3+) CTC/7.5 ml (HER2 IF: 0, 1+, 2+, 3+)       
IS and M0   IHC, FISH  CellSearch® ≥1 CTC/22.5 ml  IS: 6/73 (8%)  5/12 (41%)  5/5 (100%)  [59]
    ≥1 HER2+ CTC/22.5 ml  M0:12/101(12%)     
    HER2 Intensity CellSearch® ≥ 2.5       
M0 and M1  IHC, FISH, CISH  CellSearch®   40/66 (61%)  8/28 (29%)  7/12 (58%)  [76]
   ≥2  CTCs/7.5ml       
    ≥50%HER2+ CTCs (HER2 IF: -, +)       
M1  IHC, FISH  AdnaTest®, RT-PCR  22/42 (52%)  5/17 (29%)  2/5 (40%)  [66]
M1  IHC, FISH  AdnaTest®, RT-PCR  90/229 (30%)  28/57 (49%)  9/22 (41%)  [42]
    CellSearch®   122/245 (50%)  25/76 (33%)  18/31 (58%) 
    ≥5 CTCs/7.5 ml       
    ≥1 HER2 (3+) CTC/7.5 ml (HER2 IF: 0, 1+, 2+, 3+)       
M1  IHC, FISH,   CellSearch® ≥1 CTC/7.5 ml  57/76 (75%)  6/42 (14%)  13/15 (87%)  [77]
    ≥1 HER2+ CTC/7.5 ml (HER2 IF: -, +)       
M1  IHC, FISH  CellSearch® Profi  ling Kit, FISH for HER2  75/75 (100%)  10/30 (33%)  44/45 (98%)  [78]
    ≥1 CTC/7.5 ml       
    HER2+ CTCs: FISH HER2/CEP17 ≥2.0       
M1  IHC, FISH  CellSearch® ≥1 CTC/7.5 ml  29/38 (76%)  3/18 (16%)  9/11 (82%)  [33]
    HER2 IF: 0, 1+, 2+, 3+       
    H-score ≥200 for HER2 IF       
CISH, chromogenic in situ hybridization; CTC, circulating tumor cell; EpCAM, epithelial cell adhesion molecule; FISH, fl  uorescent in situ hybridization; ICC, 
immunocytochemistry; IF, immunofl  uoresence; IHC, immunohistochemistry; IS, ductal/lobular carcinoma in situ; M0, non-metastatic; M1, metastatic; NA, not available; 
NAC, neoadjuvant chemotherapy; PT, primary tumor; RT-PCR, reverse transcription PCR.
Ignatiadis and Reinholz Breast Cancer Research 2011, 13:222 
http://breast-cancer-research.com/content/13/5/222
Page 6 of 10system [93]. When there are limitations in blood supply 
and/or when there is an active immune system, for 
example, the micrometastasis cannot grow into overt 
metastasis. By contrast, a shift in favor of pro-angiogenic 
factors and activation of transcriptional programs that 
allow the recruitment of new blood vessels (angiogenic 
switch) or an escape of immune surveillance (immuno-
supression) may cause the expansion of the micrometa-
static cells into macrometastasis. It is not clear how all 
these mechanisms operate in a given patient, or how they 
are inﬂ  uenced by exogenous factors like stress and diet or 
by host genetic factors [94].
Genomic characterization of DTCs/CTCs
Th   us far, only limited information is available about the 
global gene expression programs that determine the fate 
of DTCs and CTCs. Some studies have performed 
molecular characterization of CTC-enriched samples 
and reported mRNA or microRNA expression of CTC-
speciﬁ  c genes in metastatic BC [95,96]. Using single cell 
comparative genomic hybridization, it has been shown 
that bone marrow DTCs are genetically heterogeneous 
and display fewer genetic aberrations than primary 
tumor cells [97-99]. In addition, the most prevalent 
chromo  somal aberrations of primary breast tumors 
(including 8q gain, 13q loss, 16q loss and 17p loss) have 
rarely been found in DTCs with abnormal karyograms 
isolated at the time of curative surgery [3]. Husemann 
and colleagues [100] provided evidence that systemic 
spread occurs early in BC by showing that tumor cells 
can disseminate from earliest breast epithelial alterations 
in transgenic mice and from breast ductal carcinoma in 
situ in women. Th   ese results have led to the proposal of a 
parallel progression model in which tumor cells 
disseminate early at ectopic sites and evolve in parallel 
with tumor cells in the primary site [3]. Finally, beyond 
gene expression proﬁ   ling and comparative genomic 
hybridization, the characterization of DTCs/CTCs using 
next generation sequencing may provide new insights 
into the cellular programs that regulate tumor dormancy 
and metastasis.
Future directions
Th  e characterization of DTCs/CTCs might lead to the 
identiﬁ   cation of targets for the design of new drugs. 
CTCs might also be used to accelerate drug development 
if ongoing or future trials demonstrate that CTC 
clearance is a ‘surrogate’ for drug eﬃ   cacy. In order to 
move DTCs/CTCs into clinical practice, prospective 
trials with innovative designs and endpoints are needed 
to demonstrate both clinical utility and cost-eﬀ  ectiveness. 
Such eﬀ  orts are currently ongoing. Because the techno  lo-
gies used to detect and characterize tumor cells in 
peripheral blood are rapidly evolving, issues like easy 
access to newer technologies and standardization across 
laboratories will be critical for prospective validation. 
CTC detection and characterization have the potential to 
improve risk assessment and provide a ‘liquid biopsy’ for 
real-time monitoring of tumor genotype/phenotype in 
metastatic BC. In early BC, the presence of MRD after 
patients have completed standard adjuvant treatment 
may contribute to a better selection of patients to evalu-
ate secondary adjuvant treatment strategies. Overall, the 
integration of information from both the primary tumor 
and MRD may eventually lead to personalized treatment 
strategies.
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